PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBempedoic acid
Nexletol, Nilemdo(bempedoic acid)
Nexletol, Nexlizet, Nilemdo, Nustendi (bempedoic acid) is a small molecule pharmaceutical. Bempedoic acid was first approved as Nexletol on 2020-02-21. It is used to treat atherosclerosis and hyperlipoproteinemia type II in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia.
Download report
Favorite
FDA Novel Drug Approvals 2020
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Nexletol
Combinations
Nexlizet
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bempedoic acid
Tradename
Company
Number
Date
Products
NEXLETOLEsperion TherapeuticsN-211616 RX2020-02-21
1 products, RLD, RS
Bempedoic acid
+
Ezetimibe
Tradename
Company
Number
Date
Products
NEXLIZETEsperion TherapeuticsN-211617 RX2020-02-26
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
nexletolNew Drug Application2025-07-24
nexlizetNew Drug Application2025-07-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atherosclerosisEFO_0003914D050197I25.1
hyperlipoproteinemia type iiEFO_0004911D006938E78.00
hypercholesterolemia—D006937—
familial combined hyperlipidemiaEFO_0000492D006950E78.49
Agency Specific
FDA
EMA
Expiration
Code
BEMPEDOIC ACID, NEXLETOL, ESPERION THERAPS INC
2025-02-21NCE
BEMPEDOIC ACID / EZETIMIBE, NEXLIZET, ESPERION THERAPS INC
2025-02-21NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Bempedoic Acid, Nexletol, Esperion Theraps Inc
116135112040-06-19DP
117607142040-06-19DP
73357992025-12-03DP
Bempedoic Acid / Ezetimibe, Nexlizet, Esperion Theraps Inc
109127512036-03-14U-3224
117448162036-03-14U-3692
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AX: Other lipid modifying agents in atc
— C10AX15: Bempedoic acid
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA10: Bempedoic acid and ezetimibe
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hyperlipoproteinemia type iiD006938EFO_0004911E78.00———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD006937——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBempedoic acid
INNbempedoic acid
Description
Bempedoic acid is an alpha,omega-dicarboxylic acid that is pentadecanedioic acid which is substituted by methyl groups groups at positions 2 and 14, and by a hydroxy group at position 8. It is a drug used for the treatment of high LDL cholesterol, which is sometimes referred to as 'bad cholesterol'. It has a role as an antilipemic drug, an EC 2.3.3.8 (ATP citrate synthase) inhibitor and a prodrug.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O
Identifiers
PDB—
CAS-ID738606-46-7
RxCUI—
ChEMBL IDCHEMBL3545313
ChEBI ID—
PubChem CID10472693
DrugBankDB11936
UNII ID1EJ6Z6Q368 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,423 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,636 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use